Qualified Person (QP) concept and MA transfers in EU MCQs With Answer

Introduction: Qualified Person (QP) concept and MA transfers in EU MCQs With Answer — This quiz set is designed for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics. It covers the EU Qualified Person role, responsibilities and legal basis, practical aspects of batch certification, importation and GMP compliance, and the regulatory pathways and requirements when transferring a Marketing Authorisation (MA) within the EU (centralised, mutual recognition, decentralised and national procedures). Questions emphasise Annex 16 (EU GMP), the CTD dossier implications, roles of the MA holder and competent authorities, and common pitfalls during MA transfers. These MCQs deepen understanding for regulatory practice and exam preparation.

Q1. What is the primary legal source in EU law that established the requirement for a Qualified Person (QP) to certify medicinal product batches?

• The EU Clinical Trials Regulation (CTR)
• The EU Pharmacovigilance Directive
• The Medicinal Products Directive 2001/83/EC
• The EU Cosmetics Regulation

Correct Answer: The Medicinal Products Directive 2001/83/EC

Q2. Which document of the EU GMP guidance contains the detailed responsibilities and principles for the Qualified Person and batch certification?

• Annex 1 — Sterile Medicinal Products
• Annex 16 — Certification by a Qualified Person and Batch Release
• Annex 11 — Computerised Systems
• Part I — Pharmaceutical Quality System

Correct Answer: Annex 16 — Certification by a Qualified Person and Batch Release

Q3. Which of the following is a core responsibility of a QP before certifying a batch for release?

• Approving the marketing strategy and pricing
• Ensuring batch documentation shows compliance with the marketing authorisation and GMP
• Designing clinical trial protocols
• Marketing the product to healthcare professionals

Correct Answer: Ensuring batch documentation shows compliance with the marketing authorisation and GMP

Q4. Under EU practice, who holds ultimate legal responsibility for ensuring compliance with the marketing authorisation — including during an MA transfer?

• The Qualified Person at the receiving site only
• The Marketing Authorisation Holder (MAH)
• The contract manufacturer exclusively
• The national pharmacy inspectorate regardless of MAH

Correct Answer: The Marketing Authorisation Holder (MAH)

Q5. Which CTD module is typically most affected and must be updated during a transfer of the marketing authorisation related to manufacturing changes?

• Module 1 — Regional Administrative Information
• Module 2 — Quality Overall Summary
• Module 3 — Quality (Chemistry, Manufacturing and Controls)
• Module 5 — Clinical Study Reports

Correct Answer: Module 3 — Quality (Chemistry, Manufacturing and Controls)

Q6. When transferring an MA from one holder to another within the same EU Member State, the regulatory submission is usually processed as:

• A new centralised marketing authorisation application
• A variation or administrative change to the existing MA (change of MAH)
• A clinical trial application
• An automatic mutual recognition without submission

Correct Answer: A variation or administrative change to the existing MA (change of MAH)

Q7. According to Annex 16, how must a QP establish that a batch manufactured at a third-country site complies with EU GMP prior to release in the EU?

• Rely solely on a certificate provided by the third-country manufacturer
• Ensure that either the site is regularly inspected by EU authorities or that appropriate GMP equivalence and control evidence is obtained
• Accept a written statement from the MAH without evidence
• No additional checks are needed for third-country sites

Correct Answer: Ensure that either the site is regularly inspected by EU authorities or that appropriate GMP equivalence and control evidence is obtained

Q8. In the context of MA transfers, what is the key risk that must be managed to avoid interruptions in supply during change of MAH?

• Failure to rebrand the product immediately
• Regulatory timing mismatches and missing updates to labelling, batch release arrangements and distribution agreements
• Running new clinical trials for the same product
• Immediate cessation of all contract manufacturing

Correct Answer: Regulatory timing mismatches and missing updates to labelling, batch release arrangements and distribution agreements

Q9. Which procedure would you use to obtain a single EU-wide MA that is valid in all Member States?

• National procedure
• Mutual Recognition Procedure (MRP)
• Decentralised Procedure (DCP)
• Centralised Procedure via EMA

Correct Answer: Centralised Procedure via EMA

Q10. During a marketing authorisation transfer where the site of manufacture is unchanged but the MAH changes, which of the following is most likely to be required?

• Complete repeat of all non-clinical studies
• Administrative update of MAH details and possible Type IA/IB or national variation depending on national rules
• Automatic revocation of the original MA
• New marketing authorisation via centralised procedure

Correct Answer: Administrative update of MAH details and possible Type IA/IB or national variation depending on national rules

Q11. Which statement best describes the QP’s role when a batch shows a specification deviation that has a potential impact on patient safety?

• The QP must release the batch immediately and report later
• The QP may certify release only if the MAH provides commercial justification
• The QP must ensure that a formal investigation has concluded and that the batch is compliant with the MA and GMP before certifying
• The QP can delegate final decision to the head of production without review

Correct Answer: The QP must ensure that a formal investigation has concluded and that the batch is compliant with the MA and GMP before certifying

Q12. What is a common regulatory requirement when transferring the marketing authorisation for a biological medicinal product?

• No documentation is required because biologics are exempt from transfer rules
• Comprehensive comparability data and detailed Quality (Module 3) updates are often required to demonstrate equivalence
• Only Module 5 needs updating
• Biologicals automatically transfer without MAH notification

Correct Answer: Comprehensive comparability data and detailed Quality (Module 3) updates are often required to demonstrate equivalence

Q13. When parallel distribution (parallel import or supply) involves a different EU Member State, what is a key QP consideration?

• The QP can ignore differences in labelling and packaging
• The QP must ensure that the product conforms to the destination Member State’s labelling and legal requirements and that the batch is compliant with the MA
• The QP should request a new clinical trial in the destination country
• The QP is not involved in parallel distribution

Correct Answer: The QP must ensure that the product conforms to the destination Member State’s labelling and legal requirements and that the batch is compliant with the MA

Q14. Which of the following describes the decentralised procedure (DCP) for obtaining an MA in the EU?

• A single application to the EMA that covers all Member States
• A simultaneous application to several Member States where one chosen Reference Member State evaluates and others accept its assessment
• Only applicable for generic products
• A national procedure that cannot be recognised elsewhere

Correct Answer: A simultaneous application to several Member States where one chosen Reference Member State evaluates and others accept its assessment

Q15. If a QP relies on Certificates of Analysis (CoA) from a contract laboratory, what is an expected QP action before batch certification?

• Discard CoA and perform no checks
• Verify the CoA origin, method suitability, and that the laboratory operates under appropriate quality systems and GMP expectations
• Ask the MAH to ignore the CoA
• Release the batch without any review of CoA

Correct Answer: Verify the CoA origin, method suitability, and that the laboratory operates under appropriate quality systems and GMP expectations

Q16. When the marketing authorisation is transferred and the name/address of the MAH is changed, which section of Module 1 typically requires update?

• Module 3 — Quality
• Module 1 — Administrative information and prescribing information (regional)
• Module 4 — Non-clinical reports
• Module 5 — Clinical efficacy data

Correct Answer: Module 1 — Administrative information and prescribing information (regional)

Q17. Which of the following is NOT a responsibility of the Qualified Person under Annex 16?

• Confirming that each production batch has been manufactured and tested in accordance with the requirements of the marketing authorisation
• Ensuring that the goods are released only by a QP established in the EU for each batch placed on the EU market
• Developing marketing materials targeted to prescribers
• Ensuring investigations are completed before release when deviations affect compliance

Correct Answer: Developing marketing materials targeted to prescribers

Q18. During an MA transfer involving a change in the site of manufacture, what regulatory evidence is generally expected?

• No evidence; change of manufacture is always administrative
• Data or justification showing that the new site can manufacture the product to the same quality (e.g., validation, GMP compliance, stability bridging if necessary)
• Only a new artwork for labels
• Immediate discontinuation of the old site without inspection

Correct Answer: Data or justification showing that the new site can manufacture the product to the same quality (e.g., validation, GMP compliance, stability bridging if necessary)

Q19. What is the expected relationship between the QP and the MAH once an MA transfer is complete?

• The QP is independent and has no communication with the MAH
• The QP should have clear documented communication, access to batch records and authority to prevent release if non-compliance is found; the MAH remains accountable
• The MAH automatically assumes the QP duties
• The QP’s role ends immediately after transfer

Correct Answer: The QP should have clear documented communication, access to batch records and authority to prevent release if non-compliance is found; the MAH remains accountable

Q20. Which regulatory pathway is most appropriate if an applicant seeks recognition in one Member State based on an MA already granted in another Member State?

• Centralised Procedure
• Mutual Recognition Procedure (MRP)
• Decentralised Procedure
• New clinical trials application

Correct Answer: Mutual Recognition Procedure (MRP)

Download